Encorafenib and Binimetinib: First Global Approvals

2018/08/01 by Matt Shirley · 25 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Computer Science · #Melanoma and MAPK Pathways #Colorectal Cancer Treatments and Studies #Computational Drug Discovery Methods

paper · doi:10.1007/s40265-018-0963-x

Cited by

• miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A. [europepmc]
• In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. [europepmc]
• Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy. [europepmc]
• Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma. [europepmc]
• The Role of Immune Checkpoint Blockade in Uveal Melanoma. [europepmc]
• Current Advances in the Treatment of BRAF-Mutant Melanoma. [europepmc]
• Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. [europepmc]
• BRAF mutation and its inhibitors in sarcoma treatment. [europepmc]
• Discovering Anti-Cancer Drugs via Computational Methods. [europepmc]
• Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. [europepmc]
• Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. [europepmc]
• Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non-small-Cell Lung Cancer In Vivo and In Vitro . [europepmc]
• Oxidative Stress and Autophagy as Key Targets in Melanoma Cell Fate. [europepmc]
• FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. [europepmc]
• Emerging Promise of Computational Techniques in Anti-Cancer Research: At a Glance. [europepmc]
• M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma. [europepmc]
• Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. [europepmc]
• The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma. [europepmc]
• Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells. [europepmc]
• Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016-2020): A Recapitulation of Chirality. [europepmc]
• Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. [europepmc]
• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. [europepmc]
• Recent advances in multitarget-directed ligands via in silico drug discovery. [europepmc]
• Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. [europepmc]
• FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. [europepmc]